Page last updated: 2024-10-30

edaravone and CACH Syndrome

edaravone has been researched along with CACH Syndrome in 1 studies

Research Excerpts

ExcerptRelevanceReference
"Edaravone treatment reduced differential VWMD protein expression of the UPR, phagosome regulation, ubiquitination, autophagy, ER stress, senescence, and TCA cycle pathways."1.91Edaravone and mitochondrial transfer as potential therapeutics for vanishing white matter disease astrocyte dysfunction. ( Carroll, L; Chung, J; Maksour, S; Newbery, M; Ng, NS; Ooi, L; Touffu, A; Wu, Y; Zaw, T, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Ng, NS1
Newbery, M1
Touffu, A1
Maksour, S1
Chung, J1
Carroll, L1
Zaw, T1
Wu, Y1
Ooi, L1

Other Studies

1 other study available for edaravone and CACH Syndrome

ArticleYear
Edaravone and mitochondrial transfer as potential therapeutics for vanishing white matter disease astrocyte dysfunction.
    CNS neuroscience & therapeutics, 2023, Volume: 29, Issue:9

    Topics: Astrocytes; Edaravone; Eukaryotic Initiation Factor-2; Humans; Leukoencephalopathies; Mitochondria;

2023